Top

Published in:

01-12-2013 | Molecular Biology (S Anant, Section Editor)

Honokiol as a Radiosensitizing Agent for Colorectal Cancers

Authors: Zhiyun He, Dharmalingam Subramaniam, Zhongtao Zhang, Youcheng Zhang, Shrikant Anant

Published in: Current Colorectal Cancer Reports | Issue 4/2013

Abstract

Radioresistance is a frustrating obstacle for patients with colorectal cancers (CRCs) undergoing radiotherapy. There is an urgent need to find an effective agent to increase the sensitivity of CRCs to radiation. Honokiol, an active compound purified from magnolia, was found to radiosensitize CRC cells both in vitro and in vivo. However, the mechanism controlling important signaling that enhances radiosensitivity is currently unknown. In this study, we review important signaling pathways that are closely related to radiosensitization, such as cell cycle arrest, tumor angiogenesis, the Jak/STAT3 signaling pathway, and mismatch repair. Studies show that honokiol can interfere with these pathways at different levels. Overall analysis may shed light on the possible mechanism by which honokiol acts as a radiosensitizing agent for CRCs.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138.PubMedCrossRef

Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010;116(19):4613–21. doi:10.1002/cncr.25350.PubMedCrossRef

•• Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med. 2012;12(10):1244–52. This review focuses on honokiol's multiple functions, including anti-inflammatory, antiangiogenic, antioxidative, and anticancer properties.PubMedCrossRef

Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-κB activation pathway. Mol Cancer Res. 2006;4(9):621–33. doi:10.1158/1541-7786.MCR-06-0076.PubMedCrossRef

Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 2012;227(5):2184–95. doi:10.1002/jcp.22954.PubMedCrossRef

•• He Z, Subramaniam D, Ramalingam S, Dhar A, Postier RG, Umar S, et al. Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G929–37. doi:10.1152/ajpgi.00159.2011. This article first showed that honokiol radiosensitizes CRC cells and also that MMR plays a vital role during the radiosensitizing process.PubMedCrossRef

•• Ponnurangam S, Mammen JM, Ramalingam S, He Z, Zhang Y, Umar S, et al. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol Cancer Ther. 2012;11(4):963–72. doi:10.1158/1535-7163.MCT-11-0999. This article showed honokiol in combination with radiation affects colon cancer stem cell growth, thereby inhibiting the γ-secretase complex and the Notch signaling pathway.PubMedCrossRef

Tell R, Edgren MR, Sverrisdottir A, Castro J, Fornander T, Hansson LO, et al. Radiation-induced cell cycle response in lymphocytes is not related to clinical side-effects in breast cancer patients. Anticancer Res. 2003;23(3C):3077–83.PubMed

Khaitan D, Chandna S, Arya MB, Dwarakanath BS. Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line. Cancer Biol Ther. 2006;5(9):1142–51.PubMedCrossRef

10.

Sak A, Stuschke M, Groneberg M, Kubler D, Pottgen C, Eberhardt WE. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Int J Radiat Oncol Biol Phys. 2012;84(2):492–9. doi:10.1016/j.ijrobp.2011.12.021.PubMedCrossRef

11.

• Zhao Y, Cui Y, Han J, Ren J, Wu G, Cheng J. Cell division cycle 25 homolog c effects on low-dose hyper-radiosensitivity and induced radioresistance at elevated dosage in A549 cells. J Radiat Res. 2012;53(5):686–94. doi:10.1093/jrr/rrs024. This study revealed the underlying relationship between radiosensitivity and radioresistance with regard to CDC25 expression, and elucidated a possible relation between the cell cycle and radiosensitivity.PubMedCrossRef

12.

Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res. 2008;14(4):1248–57. doi:10.1158/1078-0432.CCR-07-1926.PubMedCrossRef

13.

Sahin M, Sahin E, Gumuslu S. Cyclooxygenase-2 in cancer and angiogenesis. Angiology. 2009;60(2):242–53. doi:10.1177/0003319708318378.PubMed

14.

• Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011;286(17):15332–43. doi:10.1074/jbc.M110.212514. This article showed that the effect of YKL-40 on VEGF expression is closely related to angiogenesis and plays a mediating effect between radioresistance and angiogenesis.PubMedCrossRef

15.

Cerqueira A, Santamaria D, Martinez-Pastor B, Cuadrado M, Fernandez-Capetillo O, Barbacid M. Overall Cdk activity modulates the DNA damage response in mammalian cells. J Cell Biol. 2009;187(6):773–80. doi:10.1083/jcb.200903033.PubMedCrossRef

16.

Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28(5):739–45. doi:10.1016/j.molcel.2007.11.015.PubMedCrossRef

17.

Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005;434(7033):605–11. doi:10.1038/nature03442.PubMedCrossRef

18.

Matsuoka S, Ballif BA, Smogorzewska A, McDonald 3rd ER, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160–6. doi:10.1126/science.1140321.PubMedCrossRef

19.

Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z, et al. Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem. 2005;280(24):23262–72. doi:10.1074/jbc.M503701200.PubMedCrossRef

20.

Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 2002;8(1):47–54.PubMedCrossRef

21.

Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51. doi:10.3389/fnmol.2011.00051.PubMedCrossRef

22.

Kang FW, Que L, Wu M, Wang ZL, Sun J. Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol Rep. 2012;28(1):193–9. doi:10.3892/or.2012.1784.PubMed

23.

Magnon C, Opolon P, Ricard M, Connault E, Ardouin P, Galaup A, et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J Clin Invest. 2007;117(7):1844–55. doi:10.1172/JCI30269.PubMedCrossRef

24.

• Sofia Vala I, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 2010;5(6):e11222. doi:10.1371/journal.pone.0011222. This article demonstrated the mutual effect of radiation and tumor angiogenesis, and it shed light on the radiosensitizing effects of tumor angiogenesis.PubMedCrossRef

25.

Xu Z, Fang S, Zuo Y, Zhang Y, Cheng R, Wang Q, et al. Combination of pigment epithelium-derived factor with radiotherapy enhances the antitumor effects on nasopharyngeal carcinoma by downregulating vascular endothelial growth factor expression and angiogenesis. Cancer Sci. 2011;102(10):1789–98. doi:10.1111/j.1349-7006.2011.02013.x.PubMedCrossRef

26.

Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 1994;55(13):1061–9.PubMedCrossRef

27.

Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003;278(37):35501–7. doi:10.1074/jbc.M302967200.PubMedCrossRef

28.

Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. 2005;106(2):690–7. doi:10.1182/blood-2004-11-4273.PubMedCrossRef

29.

Singh-Gupta V, Zhang H, Banerjee S, Kong D, Raffoul JJ, Sarkar FH, et al. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer. 2009;124(7):1675–84. doi:10.1002/ijc.24015.PubMedCrossRef

30.

Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 2003;63(13):3755–63.PubMed

31.

Rahaman SO, Vogelbaum MA, Haque SJ. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Rα2. Cancer Res. 2005;65(7):2956–63. doi:10.1158/0008-5472.CAN-04-3592.PubMedCrossRef

32.

Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41(16):2502–12. doi:10.1016/j.ejca.2005.08.016.PubMedCrossRef

33.

Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006;66(8):3963–6. doi:10.1158/0008-5472.CAN-06-0743.PubMedCrossRef

34.

Sun Y, Cheng MK, Griffiths TR, Mellon JK, Kai B, Kriajevska M, et al. Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation. Curr Cancer Drug Targets. 2013;13(1):57–68.PubMedCrossRef

35.

Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. Sci World J. 2010;10:413–8. doi:10.1100/tsw.2010.44.CrossRef

36.

•• Sun Y, Moretti L, Giacalone NJ, Schleicher S, Speirs CK, Carbone DP, et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol. 2011;6(4):699–706. doi:10.1097/JTO.0b013e31820d9d11. This study indicated that Jak2/STAT3 signaling pathway inhibition can enhance the sensitivity of lung cancer cells to radiation, which reveals the Jak2/STAT3 signaling pathway may play an important role in cancer cell radiosensitization.PubMedCrossRef

37.

Pan Y, Zhou F, Zhang R, Claret FX. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One. 2013;8(1):e54565. doi:10.1371/journal.pone.0054565.PubMedCrossRef

38.

Ishikawa C, Arbiser JL, Mori N. Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia. Biochim Biophys Acta. 2012;1820(7):879–87. doi:10.1016/j.bbagen.2012.03.009.PubMedCrossRef

39.

•• Yu C, Zhang Q, Zhang HY, Zhang X, Huo X, Cheng E, et al. Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol. 2012;303(5):G561–9. doi:10.1152/ajpgi.00033.2012. STAT3 contributes to the intrinsic inflammatory pathway, which can link chronic inflammation with cancer. This study demonstrated that honokiol inhibits proliferation and induces apoptosis by activating the intrinsic inflammatory pathway.PubMedCrossRef

40.

Liu SH, Wang KB, Lan KH, Lee WJ, Pan HC, Wu SM, et al. Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice. PLoS One. 2012;7(8):e43711. doi:10.1371/journal.pone.0043711.PubMedCrossRef

41.

Pan HC, Lai DW, Lan KH, Shen CC, Wu SM, Chiu CS, et al. Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model. Carcinogenesis. 2013. doi:10.1093/carcin/bgt243.

42.

•• Lee SH, Hong HS, Liu ZX, Kim RH, Kang MK, Park NH, et al. TNFα enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells. Biochem Biophys Res Commun. 2012;424(1):58–64. doi:10.1016/j.bbrc.2012.06.065. This study illustrated that TNF increases stem cell phenotype and Notch antagonists inhibit TNF-mediated proliferation.PubMedCrossRef

43.

Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 2012;322(2):139–47. doi:10.1016/j.canlet.2012.03.024.PubMedCrossRef

44.

Janikova M, Skarda J. Differentiation pathways in carcinogenesis and in chemo- and radioresistance. Neoplasma. 2012;59(1):6–17. doi:10.4149/neo_2012_002.PubMedCrossRef

45.

Yu S, Zhang R, Liu F, Wang H, Wu J, Wang Y. Notch inhibition suppresses nasopharyngeal carcinoma by depleting cancer stem-like side population cells. Oncol Rep. 2012;28(2):561–6. doi:10.3892/or.2012.1830.PubMed

46.

Wang J, Sullenger BA, Rich JN. Notch signaling in cancer stem cells. Adv Exp Med Biol. 2012;727:174–85. doi:10.1007/978-1-4614-0899-4_13.PubMedCrossRef

47.

Han ME, Oh SO. Gastric stem cells and gastric cancer stem cells. Anat Cell Biol. 2013;46(1):8–18. doi:10.5115/acb.2013.46.1.8.PubMedCrossRef

48.

Seveno C, Loussouarn D, Brechet S, Campone M, Juin P, Barille-Nion S. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res. 2012;14(3):R96. doi:10.1186/bcr3214.PubMedCrossRef

49.

Guilmeau S. Notch signaling and intestinal cancer. Adv Exp Med Biol. 2012;727:272–88. doi:10.1007/978-1-4614-0899-4_21.PubMedCrossRef

50.

Mimeault M, Batra SK. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol. 2012;3(3):32–42. doi:10.5306/wjco.v3.i3.32.PubMedCrossRef

51.

• Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 2013;17(1):30–54. doi:10.1111/jcmm.12004. This article revealed that hypoxia-inducing factors activate angiogenesis and play an important role in adjusting the intrinsic inflammatory pathways and can change the environment around a tumor, increasing the sensitivity of cancer cells to radiation.PubMedCrossRef

52.

Choi YP, Shim HS, Gao MQ, Kang S, Cho NH. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett. 2011;307(1):62–71. doi:10.1016/j.canlet.2011.03.018.PubMedCrossRef

53.

Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011;71(18):6010–8. doi:10.1158/0008-5472.CAN-11-0595.PubMedCrossRef

54.

Chen SM, Liu JP, Zhou JX, Chen C, Deng YQ, Wang Y, et al. Suppression of the notch signaling pathway by γ-secretase inhibitor GSI inhibits human nasopharyngeal carcinoma cell proliferation. Cancer Lett. 2011;306(1):76–84. doi:10.1016/j.canlet.2011.02.034.PubMedCrossRef

55.

Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E, Coombes RC. Inhibition of γ-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer. 2009;100(12):1879–88. doi:10.1038/sj.bjc.6605034.PubMedCrossRef

56.

Yan T, Seo Y, Kinsella TJ. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res. 2009;15(22):6912–20. doi:10.1158/1078-0432.CCR-09-1698.PubMedCrossRef

57.

Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res. 2003;63(20):6935–41.PubMed

58.

Luo H, Zhong Q, Chen LJ, Qi XR, Fu AF, Yang HS, et al. Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer. J Cancer Res Clin Oncol. 2008;134(9):937–45. doi:10.1007/s00432-008-0375-5.PubMedCrossRef

59.

Liu Y, Chen L, He X, Fan L, Yang G, Chen X, et al. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. Int J Gynecol Cancer. 2008;18(4):652–9. doi:10.1111/j.1525-1438.2007.01070.x.PubMedCrossRef

60.

Mahadevan B, Marston CP, Dashwood WM, Li Y, Pereira C, Baird WM. Effect of a standardized complex mixture derived from coal tar on the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons in human cells in culture. Chem Res Toxicol. 2005;18(2):224–31. doi:10.1021/tx0497604.PubMedCrossRef

Title: Honokiol as a Radiosensitizing Agent for Colorectal Cancers
Authors: Zhiyun He
Dharmalingam Subramaniam
Zhongtao Zhang
Youcheng Zhang
Shrikant Anant
Publication date: 01-12-2013
Publisher: Springer US
Published in: Current Colorectal Cancer Reports / Issue 4/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-013-0191-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Molecular Origins of Colon and Rectal Cancer: Not a Wnt–Wnt Situation

Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?

How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?

Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer

Oncotype DX for Colon Cancer: Are We Ready for Prime Time in Personalized Medicine?

The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer